The capital injection arrives as Altius seeks to stabilize its balance sheet following a series of acquisitions slated for 2026. Management intends to use the proceeds to bolster liquidity and maintain a conservative leverage profile, a strategy supported by concurrent adjustments to the company's credit facilities. Despite the sharp intraday drop, the stock maintains a 10% gain over the last three months.

The offering is expected to finalize around July 21, contingent on regulatory clearance from the Toronto Stock Exchange. Shares are being marketed via prospectus supplement across Canada, excluding Québec and Nunavut, with provisions for sales to qualified institutional buyers in the United States.